{"id":"cyclosporine-a-eye-drops-0-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation / burning sensation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Foreign body sensation"},{"rate":null,"effect":"Transient blurred vision"}]},"_chembl":{"chemblId":"CHEMBL406352","moleculeType":"Small molecule","molecularWeight":"1202.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine A is a calcineurin inhibitor that blocks the dephosphorylation of nuclear factor of activated T cells (NFAT), preventing T-cell activation and the production of pro-inflammatory cytokines such as IL-2. In the eye, this immunosuppressive action reduces inflammation associated with dry eye disease and other ocular surface inflammatory conditions. The 0.5% ophthalmic formulation delivers the drug topically to the ocular surface.","oneSentence":"Cyclosporine A suppresses T-cell activation and proliferation by inhibiting calcineurin, reducing inflammatory cytokine production in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:02.094Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"},{"name":"Ocular surface inflammation"}]},"trialDetails":[{"nctId":"NCT04555694","phase":"PHASE4","title":"Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax","status":"COMPLETED","sponsor":"Thomas Chester, OD","startDate":"2020-10-01","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT04127851","phase":"PHASE4","title":"Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2019-11-12","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":438},{"nctId":"NCT05353101","phase":"PHASE1","title":"Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2020-07-01","conditions":"Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops","enrollment":48},{"nctId":"NCT02004067","phase":"PHASE4","title":"Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2013-01","conditions":"Primary Sjogren Syndrome, Secondary Sjogren Syndrome, Aqueous Deficient Dry Eye Disease","enrollment":100},{"nctId":"NCT04376970","phase":"PHASE4","title":"Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Military Hospital of Tunis","startDate":"2017-04-01","conditions":"Adenoviral Keratoconjunctivitis","enrollment":51},{"nctId":"NCT01817582","phase":"PHASE2","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-05-17","conditions":"Keratoconjunctivitis Sicca","enrollment":102},{"nctId":"NCT02028312","phase":"PHASE4","title":"A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®","status":"WITHDRAWN","sponsor":"Edward Holland, MD","startDate":"2014-01","conditions":"Dry Eye Disease","enrollment":""},{"nctId":"NCT02011776","phase":"","title":"A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome","status":"COMPLETED","sponsor":"Santen Pharmaceutical(China) Co.,LTD","startDate":"2013-03","conditions":"Dry Eye Syndromes, Sjögren Syndrome","enrollment":35},{"nctId":"NCT00797030","phase":"PHASE4","title":"Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus","status":"UNKNOWN","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2006-10","conditions":"Dry Eye Syndromes, HIV Seropositivity","enrollment":20},{"nctId":"NCT00433277","phase":"NA","title":"Autoimmunity in Retinitis Pigmentosa","status":"UNKNOWN","sponsor":"Semmelweis University","startDate":"","conditions":"Retinitis Pigmentosa","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CsA"],"phase":"marketed","status":"active","brandName":"Cyclosporine A eye drops 0.5%","genericName":"Cyclosporine A eye drops 0.5%","companyName":"Military Hospital of Tunis","companyId":"military-hospital-of-tunis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine A suppresses T-cell activation and proliferation by inhibiting calcineurin, reducing inflammatory cytokine production in the eye. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}